Physician profile
Judson W Smith
NPI 1720037450
$527.68
in general payments reported to CMS, 2019-2025
23 companies · $89.22 in 2025
The $89.22 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.46 · 2020: $62.54 · 2021: $95.58 · 2022: $111 · 2023: $95.00 · 2025: $89.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $69.60 | 2022-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $53.34 | 2019-2022 | |
| Lilly USA, LLC | $39.85 | 2022-2023 | Mounjaro |
| Dexcom, INC. | $34.39 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $32.28 | 2020-2021 | |
| Pfizer INC. | $27.23 | 2019 | |
| Almatica Pharma LLC | $25.72 | 2021-2022 | |
| Sobi, INC | $23.89 | 2020 | |
| Horizon Therapeutics Plc | $18.99 | 2023 | Krystexxa |
| Hologic Sales and Service, LLC | $18.26 | 2022 | |
| Novo Nordisk INC | $18.07 | 2023 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.42 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $16.95 | 2025 | Vaxneuvance, Enflonsia, Gardasil 9 |
| Exact Sciences Corporation | $15.95 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $15.51 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15.29 | 2021 | |
| Aytu Biopharma, INC. | $13.19 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.79 | 2021 | |
| Amgen INC. | $12.00 | 2019 | |
| Genentech USA, INC. | $11.93 | 2020 | |
| Adlon Therapeutics L.P. | $11.75 | 2021 | |
| Allergan, INC. | $11.70 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judson Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.